Characteristics of surgically resected non‐small cell lung cancer patients with post‐recurrence cure

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial

(2017) Bing Sun et al.   Journal of Thoracic Oncology

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

(2017) Jean-Charles Soria et al.   LANCET

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

(2017) Toyoaki Hida et al.   LANCET

Optimising treatment for post-operative lung cancer recurrence

(2016) Dragan Subotic et al.   EUROPEAN RESPIRATORY JOURNAL

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

(2016) Glenwood Goss et al.   LANCET ONCOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pooled analysis for surgical treatment for isolated adrenal metastasis and non-small cell lung cancer

(2016) Xin-Liang Gao et al.   Interactive Cardiovascular and Thoracic Surgery

Postoperative oligo-recurrence of non-small-cell lung cancer: clinical features and survival

(2015) Tomoyuki Hishida et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

(2014) L. Friboulet et al.   Cancer Discovery

Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer

(2013) Delphine Gourcerol et al.   EUROPEAN RESPIRATORY JOURNAL

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Recurrence After Complete Resection for Non-Small Cell Lung Cancer

(2012) Matthew D. Taylor et al.   ANNALS OF THORACIC SURGERY

Results of Long-Term Follow-Up of Patients With Completely Resected Non-Small Cell Lung Cancer

(2012) Chiaki Endo et al.   ANNALS OF THORACIC SURGERY

Prognostic factors for patients in postoperative brain metastases from surgically resected non-small cell lung cancer

(2012) Jin Sakamoto et al.   International Journal of Clinical Oncology

Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy

(2012) S. Saisho et al.   Interactive Cardiovascular and Thoracic Surgery

Oligometastases and Oligo-recurrence: The New Era of Cancer Therapy

(2010) Y. Niibe et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study

(2010) Isamu Okamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer

(2010) Tokujiro Yano et al.   JOURNAL OF SURGICAL ONCOLOGY

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE